Drug Search Results
More Filters [+]

QAV680

Alternative Names: qav680
Latest Update: 2017-03-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CRTH2 Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for QAV680

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Asthma|Rhinitis, Allergic, Seasonal|Rhinitis, Allergic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2009-017267-41

P2

Completed

Asthma

2010-09-02

CQAV680A2201E1

P2

Terminated

Asthma

2010-09-01

32%

CQAV680A2204

P2

Completed

Rhinitis, Allergic

2010-07-28

2008-005168-15

P2

Completed

Asthma

2009-10-07

Recent News Events

Date

Type

Title